Clinical Trials Logo

Double-Expressor Lymphoma clinical trials

View clinical trials related to Double-Expressor Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03984448 Active, not recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Start date: October 22, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by blocking a protein called Bcl-2. Drugs used in usual chemotherapy, such as rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with usual chemotherapy may work better than usual chemotherapy alone in treating patients with high-grade B-cell lymphomas, and may increase the chance of cancer going into remission and not returning.